ResearchAndMarkets has released a market study titled "Cell and Gene Therapy Global Market Opportunities and Strategies to 2035," outlining strategic opportunities and adoption pathways for next‑generation biologics. The report frames the global cell and gene therapy sector through 2035, identifying technology, manufacturing and end‑user trends likely to shape commercial rollout.
Key technical opportunities highlighted include scalable allogeneic cell therapies, advances in gene‑editing platforms, deployment of localized CAR‑T approaches and the emergence of automated personalized manufacturing. Each area is presented as a lever to reduce costs, increase throughput or bring therapies closer to point‑of‑care, addressing current limits in bespoke autologous manufacturing and complex supply chains.
Oncology remains the priority application area in the study, with hospitals and specialized cancer care centers identified as central to clinical adoption. The report underscores that clinicians, health systems and manufacturers must coordinate on logistics, capacity and clinical workflows to integrate cell and gene treatments into routine oncology services.
Regionally, the analysis calls out Asia‑Pacific alongside other global markets as a focal area for strategic growth and investment. The study implies that developers, contract manufacturers and care providers will need to adapt business models toward scalable production and localized delivery solutions to capture opportunities through 2035.
